Samuel Kareff, MD
Hematology & Oncology · Delray Beach, FLNPI 1386149516
Payments from drug & device makers
Across 169 payments — averaging $296.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$35K
- Boehringer Ingelheim$3K
- Ipsen Biopharmaceuticals, Inc$2K
- Regeneron$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Daiichi Sankyo Inc.$842
- plus $5K from 33 others
What the payments were for
- Consulting fees$7,53752%
- Speaking & faculty fees$2,07014%
- Travel & lodging$1521%
- Food & beverage$4,20429%
- Education$6534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 4 | $34,933 |
| Boehringer Ingelheim | 6 | $3,173 |
| Ipsen Biopharmaceuticals, Inc | 5 | $2,410 |
| Regeneron | 2 | $2,142 |
| Regeneron Healthcare Solutions, Inc. | 4 | $1,465 |
| Daiichi Sankyo Inc. | 10 | $842 |
| AstraZeneca(2 entities) | 16 | $483 |
| Eli Lilly | 1 | $478 |
| Johnson & Johnson(2 entities) | 21 | $409 |
| Lantheus Medical Imaging, Inc. | 1 | $392 |
| Pfizer | 10 | $365 |
| Genentech USA, Inc. | 7 | $302 |
| Seagen Inc. | 3 | $299 |
| Gilead(2 entities) | 6 | $285 |
| Bristol Myers Squibb | 9 | $273 |
| Array Biopharma Inc | 6 | $143 |
| Sanofi | 5 | $141 |
| Cardinal Health 110 LLC | 1 | $125 |
| Merck | 5 | $107 |
| Astellas Pharma US Inc | 2 | $105 |
| Novartis | 4 | $103 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Beigene USA, Inc. | 4 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Eisai Inc. | 3 | $77 |
| Adaptive Biotechnologies Corporation | 3 | $73 |
| Novocure Inc. | 2 | $73 |
| Exelixis Inc. | 3 | $65 |
| Sobi, Inc | 1 | $62 |
| Incyte Corporation | 2 | $58 |
| Karyopharm Therapeutics Inc. | 2 | $57 |
| Caris MPI, Inc. | 2 | $53 |
| GSK | 2 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| EMD Serono, Inc. | 2 | $38 |
| Pharmaessentia USA Corporation | 1 | $31 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Genentech, Inc. | 1 | $28 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,027 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Delray Beach
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.